<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Toxins (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Toxins (Basel)</journal-id><journal-id journal-id-type="publisher-id">toxins</journal-id><journal-title-group><journal-title>Toxins</journal-title></journal-title-group><issn pub-type="epub">2072-6651</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28825663</article-id><article-id pub-id-type="pmc">5577587</article-id><article-id pub-id-type="doi">10.3390/toxins9080253</article-id><article-id pub-id-type="publisher-id">toxins-09-00253</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Efficacy of Repeated Botulinum Toxin Type A Injections for Spastic Equinus in Children with Cerebral Palsy&#x02014;A Secondary Analysis of the Randomized Clinical Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9290-6173</contrib-id><name><surname>Hong</surname><given-names>Bo Young</given-names></name><xref ref-type="aff" rid="af1-toxins-09-00253">1</xref><xref ref-type="author-notes" rid="fn1-toxins-09-00253">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9126-4316</contrib-id><name><surname>Chang</surname><given-names>Hyun Jung</given-names></name><xref ref-type="aff" rid="af2-toxins-09-00253">2</xref><xref ref-type="author-notes" rid="fn1-toxins-09-00253">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Sang-Jee</given-names></name><xref ref-type="aff" rid="af3-toxins-09-00253">3</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Soyoung</given-names></name><xref ref-type="aff" rid="af4-toxins-09-00253">4</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Joo Hyun</given-names></name><xref ref-type="aff" rid="af5-toxins-09-00253">5</xref></contrib><contrib contrib-type="author"><name><surname>Kwon</surname><given-names>Jeong-Yi</given-names></name><xref ref-type="aff" rid="af6-toxins-09-00253">6</xref><xref rid="c1-toxins-09-00253" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Jankovic</surname><given-names>Joseph</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-toxins-09-00253"><label>1</label>Department of Rehabilitation Medicine, St. Vincent&#x02019;s Hospital, College of Medicine, The Catholic University of Korea, Suwon 16247, South Korea; <email>byhong@catholic.ac.kr</email></aff><aff id="af2-toxins-09-00253"><label>2</label>Department of Physical Medicine &#x00026; Rehabilitation, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon 51353, South Korea; <email>reh.chj@gmail.com</email></aff><aff id="af3-toxins-09-00253"><label>3</label>Department of Rehabilitation Medicine, Daejeon St. Mary&#x02019;s Hospital, College of Medicine, The Catholic University of Korea, Daejeon 34943, South Korea; <email>upperlimb@catholic.ac.kr</email></aff><aff id="af4-toxins-09-00253"><label>4</label>Department of Physical Medicine &#x00026; Rehabilitation, Keimyung University, Dongsan Medical Center, Daegu 41931, South Korea; <email>sylee@dsmc.or.kr</email></aff><aff id="af5-toxins-09-00253"><label>5</label>Department of Rehabilitation Medicine, Seoul St. Mary&#x02019;s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, South Korea; <email>drpjh@catholic.ac.kr</email></aff><aff id="af6-toxins-09-00253"><label>6</label>Department of Physical and Rehabilitation Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, South Korea</aff><author-notes><corresp id="c1-toxins-09-00253"><label>*</label>Correspondence: <email>jeongyi@gmail.com</email>; Tel.: +82-2-3410-1030</corresp><fn id="fn1-toxins-09-00253"><label>&#x02020;</label><p>These authors contributed to this work equally.</p></fn></author-notes><pub-date pub-type="epub"><day>21</day><month>8</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>8</month><year>2017</year></pub-date><volume>9</volume><issue>8</issue><elocation-id>253</elocation-id><history><date date-type="received"><day>12</day><month>7</month><year>2017</year></date><date date-type="accepted"><day>18</day><month>8</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 by the authors.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Botulinum toxin A is considered an important tool to control spasticity in children with cerebral palsy. Several factors are known to affect the efficacy of botulinum toxin, such as dosage, appropriate muscle selection and application, age, and accompanying therapy. A multicenter, double-blind, randomized, prospective phase III clinical trial of botulinum toxin A for the treatment of dynamic equinus in 144 children with cerebral palsy was performed to compare the efficacies of letibotulinumtoxin A and onabotulinumtoxin A. Secondary analyses were performed to evaluate factors that affected the outcome, focusing on the number of times injections were repeated. Effectiveness was defined as a change of 2 or more in the physician&#x02019;s rating scale. Multivariate regression analyses were performed with multiple variables. The first injection of botulinum toxin A significantly improved D subscale of Gross Motor Function Measure-88 scores at 3 months compared to repeated injections (<italic>p</italic> &#x0003c; 0.05). After 6 months, patients who had one injection or none before the study showed significantly better outcomes than those who had more than one injection in terms of observational gait scores.</p></abstract><kwd-group><kwd>cerebral palsy</kwd><kwd>spasticity</kwd><kwd>botulinum toxin</kwd><kwd>onabotulinumtoxin A</kwd><kwd>letibotulinumtoxin A</kwd><kwd>equinus</kwd></kwd-group></article-meta></front><body><sec id="sec1-toxins-09-00253"><title>1. Introduction</title><p>Cerebral palsy (CP), a group of disorders in movement and posture resulting from non-progressive injury of the immature brain [<xref rid="B1-toxins-09-00253" ref-type="bibr">1</xref>], is the most common cause of disability in the pediatric population [<xref rid="B2-toxins-09-00253" ref-type="bibr">2</xref>,<xref rid="B3-toxins-09-00253" ref-type="bibr">3</xref>]. Among various subtypes grouped according to neurologic dysfunction (spastic, hypotonic, dystonic, athetotic, or others), the spastic type is the most common. It can involve unilateral or bilateral sides [<xref rid="B4-toxins-09-00253" ref-type="bibr">4</xref>,<xref rid="B5-toxins-09-00253" ref-type="bibr">5</xref>,<xref rid="B6-toxins-09-00253" ref-type="bibr">6</xref>] and accounts for 70&#x02013;80% of CP [<xref rid="B5-toxins-09-00253" ref-type="bibr">5</xref>,<xref rid="B7-toxins-09-00253" ref-type="bibr">7</xref>,<xref rid="B8-toxins-09-00253" ref-type="bibr">8</xref>]. Spasticity is defined as a velocity-dependent increase in tonic stretch reflexes (muscle tone) with exaggerated tendon jerks, resulting from hyperexcitability of the stretch reflex, as one component of the upper motor neuron syndrome [<xref rid="B9-toxins-09-00253" ref-type="bibr">9</xref>]. In CP, spasticity is known to increase up to 4 years of age, after which it decreases up to 12 years of age [<xref rid="B10-toxins-09-00253" ref-type="bibr">10</xref>]. Spasticity results in the shortening of myotendinous units, joint contracture, bony deformity, joint subluxation or dislocation, abnormal posture, and pathologic gait [<xref rid="B3-toxins-09-00253" ref-type="bibr">3</xref>]. Identifying the severity and distribution of spasticity is important in decisions about the options for managing spasticity [<xref rid="B11-toxins-09-00253" ref-type="bibr">11</xref>]. Physiotherapy and occupational therapy remain the mainstays of treatment in spastic CP [<xref rid="B3-toxins-09-00253" ref-type="bibr">3</xref>]; botulinum toxin A (BoNT) is widely used for spasticity control, and many studies support its safety and efficacy [<xref rid="B12-toxins-09-00253" ref-type="bibr">12</xref>,<xref rid="B13-toxins-09-00253" ref-type="bibr">13</xref>,<xref rid="B14-toxins-09-00253" ref-type="bibr">14</xref>].</p><p>BoNT has been commonly used to reduce muscle spasticity in children with CP since the first report of its use in 1993 [<xref rid="B15-toxins-09-00253" ref-type="bibr">15</xref>]. BoNT selectively and reversibly blocks the release of acetylcholine in the neuromuscular junction, thus reducing muscle overactivity [<xref rid="B3-toxins-09-00253" ref-type="bibr">3</xref>,<xref rid="B14-toxins-09-00253" ref-type="bibr">14</xref>,<xref rid="B16-toxins-09-00253" ref-type="bibr">16</xref>]. Although there are general side effects, injections of BoNT are known to be relatively safe [<xref rid="B17-toxins-09-00253" ref-type="bibr">17</xref>,<xref rid="B18-toxins-09-00253" ref-type="bibr">18</xref>]. Oral medications have more systemic adverse effects, such as drowsiness and sedation [<xref rid="B19-toxins-09-00253" ref-type="bibr">19</xref>], which make it hard to maintain the medications, especially in children. One of the most common indications for BoNT in ambulatory children with spastic CP involves the need to improve gait patterns [<xref rid="B12-toxins-09-00253" ref-type="bibr">12</xref>,<xref rid="B19-toxins-09-00253" ref-type="bibr">19</xref>]. Furthermore, BoNT also has positive effects on upper limb function and the kinematics of gait [<xref rid="B19-toxins-09-00253" ref-type="bibr">19</xref>,<xref rid="B20-toxins-09-00253" ref-type="bibr">20</xref>,<xref rid="B21-toxins-09-00253" ref-type="bibr">21</xref>].</p><p>The response to the treatment depends on the dosage of BoNT, appropriate administration, and adjunctive rehabilitation therapies [<xref rid="B20-toxins-09-00253" ref-type="bibr">20</xref>,<xref rid="B22-toxins-09-00253" ref-type="bibr">22</xref>,<xref rid="B23-toxins-09-00253" ref-type="bibr">23</xref>,<xref rid="B24-toxins-09-00253" ref-type="bibr">24</xref>,<xref rid="B25-toxins-09-00253" ref-type="bibr">25</xref>,<xref rid="B26-toxins-09-00253" ref-type="bibr">26</xref>]. However, there is sometimes no effect after injection of BoNT. Secondary unresponsiveness has been thought to be related to antibody formation [<xref rid="B27-toxins-09-00253" ref-type="bibr">27</xref>], but antibodies were infrequently detected in recent studies, including this clinical trial [<xref rid="B26-toxins-09-00253" ref-type="bibr">26</xref>,<xref rid="B28-toxins-09-00253" ref-type="bibr">28</xref>]. More common causes of unsatisfactory outcomes might be the wrong choice of or missed target muscles, inappropriate indications, or a lack of complementary rehabilitation treatment [<xref rid="B12-toxins-09-00253" ref-type="bibr">12</xref>]. Several studies have been performed to identify factors that affect the efficacy of BoNT in the management of spasticity of the lower extremities. Fazzi et al. showed that, compared with those older than 48 months, children aged 48 months or younger showed significantly increased gross motor function measure (GMFM) scores after 3 months of injections. Additionally, those who could walk with support showed a significantly greater increase in GMFM scores than non-walkers [<xref rid="B29-toxins-09-00253" ref-type="bibr">29</xref>]. Repeated injections of BoNT have long-term effects on gross motor function in children with CP, but the short-term effect (4 weeks) on functional improvement and reduction of spasticity was significantly higher after the first injection than after the last injection [<xref rid="B30-toxins-09-00253" ref-type="bibr">30</xref>]. Kristina et al. reported that repeated injections produced an immediate reduction in muscle tone; however, the improvement in range of motion was brief, and was noted only after the first injections [<xref rid="B31-toxins-09-00253" ref-type="bibr">31</xref>]. In a systematic review, Kahraman et al. concluded that the first two injections (one repeat) are especially effective for relieving spasticity and improving fine and gross motor activities [<xref rid="B13-toxins-09-00253" ref-type="bibr">13</xref>].</p><p>A multicenter, double-blinded, randomized, prospective phase III clinical trial (<italic>n</italic> = 144, 92 boys) of BoNT for the treatment of dynamic equinus in children with CP was undertaken recently with the primary intention of comparing the efficacy of letibotulinumtoxin A (Botulax; Hugel, Chuncheon, South Korea) and onabotulinumtoxin A (Botox; Allergan, Irvine, CA, USA). The study found injection of letibotulinum toxin A to be as effective and safe as that of onabotulinum toxin A for the treatment of dynamic equinus foot deformity in children with spastic CP (co-submitted) [<xref rid="B32-toxins-09-00253" ref-type="bibr">32</xref>]. Secondary analyses of data from those patients who completed the trial were performed to evaluate the factors that affect the efficacy of BoNT for dynamic equinus in children with CP. This report provides a more detailed evaluation in the context of these factors, focusing on the number of times the injections were repeated, which might have influenced the observational gait analysis scores and gross motor outcomes of BoNT.</p></sec><sec id="sec2-toxins-09-00253"><title>2. Results</title><sec id="sec2dot1-toxins-09-00253"><title>2.1. Physician&#x02019;s Rating Scale</title><p>A physician&#x02019;s rating scale for gait (PRS), based on that used in a trial of BoNT calf injections, was employed [<xref rid="B33-toxins-09-00253" ref-type="bibr">33</xref>]. A PRS score difference of 2 or more was considered a successful response. The numbers and percentages of successful responses in terms of PRS scores at 6, 12, and 24 weeks after BoNT injection in the calf muscles are described in <xref ref-type="table" rid="toxins-09-00253-t001">Table 1</xref>. There was a significant difference in efficacy at 6 weeks; children who had had two or fewer injections of BoNT before the study showed a better effect compared to those who had had more than two prior BoNT injections. However, there were no significant differences in the success rate between children who were first injected versus those who had been injected before, or between children who had received one or no injection versus those who were injected more than once, at 6, 12, and 24 weeks after BoNT injections. Additionally, there was no significant differences according to the limb involvement pattern (i.e., unilateral or bilateral). However, the proportion of children for whom the treatment was effective (PRS &#x02265; 2) was marginally greater, as shown by increases in the Gross Motor Function Classification System (GMFCS) level, after 24 weeks of injection (<italic>p</italic> = 0.05).</p></sec><sec id="sec2dot2-toxins-09-00253"><title>2.2. Gross Motor Function Measurement</title><p>Gross Motor Function Measure-88 (GMFM-88) total and subgroup D and E scores were evaluated to assess gross motor function. GMFM-88 scores are known to be useful outcome measures for detecting changes in gross motor function in children with CP undergoing interventions [<xref rid="B31-toxins-09-00253" ref-type="bibr">31</xref>]. The standing dimension D includes 13 items that deal with various aspects of standing. The walking, running, and jumping dimension E includes 24 items that evaluate a variety of activities that begin with standing [<xref rid="B33-toxins-09-00253" ref-type="bibr">33</xref>]. Subgroup D scores were significantly more improved in botulinum toxin-na&#x000ef;ve patients compared to patients who had had previous injections at 12 weeks (<xref ref-type="table" rid="toxins-09-00253-t002">Table 2</xref>, <italic>p</italic> = 0.042). However, there were no significant differences in total, D, and E GMFM-88 scores at 24 weeks after injection according to the number of the previous injections (<xref ref-type="table" rid="toxins-09-00253-t002">Table 2</xref>, <italic>p</italic> &#x0003e; 0.05). The mean age (SD) of the groups according to previous injection was significantly different: no previous injection (none) 3.86 (1.93), previous injection (yes) 5.66 (2.02); one or none 4.11 (1.98), more than one 5.99 (1.93); two or less 4.36 (1.98), more than two 6.39 (1.87) (<italic>p</italic> &#x0003c; 0.001).</p></sec><sec id="sec2dot3-toxins-09-00253"><title>2.3. Multivariate Regression Analyses</title><p>When patients were grouped according to the number of previous injections (none or one, two or more), the baseline PRS score was a significant predictor of outcome (PRS &#x02265; 2) at 12 weeks after injection (odds ratio = 0.825, 95% confidence interval: 0.686&#x02013;0.992, <italic>p</italic> = 0.0410; <xref ref-type="table" rid="toxins-09-00253-t003">Table 3</xref>). At 24 weeks after injection, patients with two or more previous injections had significantly poorer outcomes than those with none or one previous injection (odds ratio = 0.412, 95% confidence interval: 0.179&#x02013;0.948, <italic>p</italic> = 0.0371; <xref ref-type="table" rid="toxins-09-00253-t004">Table 4</xref>). When previous injection history was grouped as yes vs. none in the multivariate regression analyses, age, sex, baseline total PRS and GMFM-88 score, GMFCS level, type of CP (unilateral vs. bilateral), and previous injection history did not significantly impact BoNT efficacy (PRS &#x02265; 2) at 12 and 24 weeks after injection (<xref ref-type="app" rid="app1-toxins-09-00253">Tables S1 and S2</xref>). When previous injection history was grouped as three or more vs. two or less, none of the factors significantly affected BoNT efficacy at 12 and 24 weeks after injection (data not shown).</p></sec></sec><sec id="sec3-toxins-09-00253"><title>3. Discussion</title><p>The effect of BoNT on neuromuscular junction continues for 12 to 16 weeks [<xref rid="B34-toxins-09-00253" ref-type="bibr">34</xref>]. Because of the temporary effect, the injection needs to be repeated in some patients. As cerebral palsy is a lifelong disease, it is important to know the long-term effect and efficacy of repeated injections. Multivariate analyses showed that initial observational gait score (PRS) could affect the efficacy (PRS &#x02265; 2) at 12 weeks after injection, and efficacy was significantly better at 24 weeks in children who had injections once or not at all before the study than in those who had injections more than once. This result is similar to those in a recent systematic review including 13 original articles (893 children), which concluded that the first two injections were especially effective. However, this study focused on spasticity control and improvement of gross motor activities and not on gait quality [<xref rid="B13-toxins-09-00253" ref-type="bibr">13</xref>]. The effect on range of motion and reduction of spasticity occurs immediately after injection and is greater with the first injection [<xref rid="B30-toxins-09-00253" ref-type="bibr">30</xref>,<xref rid="B31-toxins-09-00253" ref-type="bibr">31</xref>], but functional improvement or maintenance of the effect could occur later in the course of the continuum of care. The difference in the scores on the standing dimension of the GMFM-88 at 3 months after the injection was significantly greater in patients who had not previously been injected compared to those who had previous injections. The ability to maintain various standing positions and to perform specific tasks from the standing position might have improved because the stability of the base of support increased significantly more through management of spasticity with BoNT in the first-injected children compared to those who had injections before. However, the total GMFM-88 and the walking, running, and jumping dimension scores did not significantly differ between first-injection and repeated-injection groups. Papavasiliou et al. reported that an important improvement occurred in the GMFM (eight-point difference) at 3 months after the first injection, but the improvement decreased with later injections in GMFCS level I&#x02013;V children [<xref rid="B35-toxins-09-00253" ref-type="bibr">35</xref>]. Injected muscles varied according to clinical needs (e.g., calf muscles, hip adductors, hamstrings) [<xref rid="B35-toxins-09-00253" ref-type="bibr">35</xref>], but only calf muscles including the gastrcocnemius and soleus were targeted in this study. Differences in the muscle selected and gross motor levels of participants might have contributed to different outcomes regarding gross motor function after BoNT injection. Also, the age should be considered in interpreting this result. The children who had no previous BoNT injection were significantly younger (3.86 vs. 5.66 years old) than those who had had injection before.</p><p>Weakness, disuse, and chronic spasticity results in muscle shortening and contracture, and these might contribute to the increase of contractures and deformities in children with CP with ageing [<xref rid="B19-toxins-09-00253" ref-type="bibr">19</xref>]. Younger age is known to be related to greater improvement in gross motor function [<xref rid="B29-toxins-09-00253" ref-type="bibr">29</xref>,<xref rid="B36-toxins-09-00253" ref-type="bibr">36</xref>,<xref rid="B37-toxins-09-00253" ref-type="bibr">37</xref>,<xref rid="B38-toxins-09-00253" ref-type="bibr">38</xref>]. Previous studies have treated age as a continuous variable or categorized it as 4 or 5 years old, younger, or older. However, in our study, multiple regression analyses showed that age was not a significant determinant of efficacy as evaluated by the PRS at 12 and 24 weeks after BoNT injection. The participants were relatively young, and the range of age was not wide. The oldest child was 10 years old, and the mean and median ages were around 5 years old, which might be the reason for the differences between our results and those of previous reports. In a study on the prognosis for gross motor function, the age at which children were expected to achieve 90% of their potential GMFM-66 score was younger than 5 years old: that is, 4.8 and 3.7 years old for those in GMFCS levels I and III, respectively [<xref rid="B39-toxins-09-00253" ref-type="bibr">39</xref>]. Also, an increase in the gross motor function score flattens after achievement of functions, which means that GMFCS level and age could affect the results. There may also have been a ceiling effect on the GMFM test itself [<xref rid="B40-toxins-09-00253" ref-type="bibr">40</xref>,<xref rid="B41-toxins-09-00253" ref-type="bibr">41</xref>], and this may have contributed to difficulty in detecting subtle changes of gross motor function.</p><p>At 24 weeks, the efficacy of BoNT measured by the PRS increased marginally as the GMFCS level increased. Although other factors were not calibrated, this means that BoNT could be more beneficial for the maintenance of the effect on the gait pattern at 6 months after the injection as the GMFCS level increases. The result differed from that of previous studies by Linder et al. and Papavasiliou et al., which found evident improvement in children at GMFCS level III [<xref rid="B38-toxins-09-00253" ref-type="bibr">38</xref>], and reported that children at GMFCS level IV gained significant enough gross motor function to change their GMFCS level [<xref rid="B35-toxins-09-00253" ref-type="bibr">35</xref>]. However, the muscles injected and the outcomes addressed were different from those in our study. Indeed, PRS scores, such as those on the GMFM-88, might not always be linked to improvements in gross motor function. Although the GMFM-88 is a useful outcome measure with which to detect changes in gross motor function in children with CP [<xref rid="B42-toxins-09-00253" ref-type="bibr">42</xref>,<xref rid="B43-toxins-09-00253" ref-type="bibr">43</xref>], it focuses on function and does not reflect the quality of movement.</p><p>As the previous studies showed different effective dose in diplegic and hemiplegic patients, hemiplegic patients required higher doses [<xref rid="B37-toxins-09-00253" ref-type="bibr">37</xref>]. This study used different doses for patients with unilateral and bilateral involvement, 3 IU/kg and 4 IU/kg, respectively, for each triceps surae. Therefore, there was no difference in their response according to the involvements of limbs, unilateral or bilateral. This also suggests that a higher dosage is needed for the children with unilateral involvement compared to bilateral involvement for a similar effect.</p><p>There are several limitations in this study. First, additional or supplemental therapies are known to be a significant influence on the outcome of BoNT injection [<xref rid="B20-toxins-09-00253" ref-type="bibr">20</xref>,<xref rid="B26-toxins-09-00253" ref-type="bibr">26</xref>], and the number of therapies or activities and the time spent performing them were not considered in this study. Also, participants were strongly advised not to change their usual therapies or activities during the clinical trial, but changing the frequency or intensity of therapies was not a cause for dropout from the study and was not investigated. Second, there are several types of BoNT available in South Korea; however, our data did not include information about what kind of BoNT the patients received before the study. Therefore, we could not investigate the cross-reactivity of BoNT preparations made by different manufacturers. Additionally, because of the 6-month observation duration, some data were missing due to the level of patients&#x02019; compliance. However, data in this study were from a multicenter, double-blind, randomized, prospective clinical trial, and the observation period for 144 spastic CP children was 6 months [<xref rid="B32-toxins-09-00253" ref-type="bibr">32</xref>]. The study provides evidence about the factors affecting outcomes, observational gait scores, and gross motor function after BoNT intervention. In conclusion, at 3 months, the first injection of BoNT for the control of dynamic tip-toeing was associated with more improvement than repeated injection with regard to the standing ability of children with CP. At 6 months after the injection, patients who had had injections once or never before the study showed significantly better outcomes in terms of observational gait scores (PRS). Age was not a significant factor affecting the efficacy (PRS) of BoNT at 12 and 24 weeks after injection.</p></sec><sec id="sec4-toxins-09-00253"><title>4. Materials and Methods</title><p>The study received permission from independent research ethics committees at each investigational site. Enrolled subjects were randomly assigned to receive letibotulinumtoxin A injection (study group, <italic>n</italic> = 70) or onabotulinumtoxin A injection (control group, <italic>n</italic> = 73) at a ratio of 1:1, and they then received the corresponding investigational products. The random assignment code was generated using a block randomization method. Those codes were sealed until the trial was completed, except in cases of serious adverse events. Participants were ambulatory children (<italic>n</italic> = 143, 91 boys) with spastic CP (GMFCS levels I&#x02013;III) who were 2&#x02013;10 years old and showed dynamic equinus deformity, tip-toe gait. The target muscles were the triceps surae, gastrocnemius, and soleus. In the case of bilateral involvement (<italic>n</italic> = 95, diplegia or tetraplegia), the investigational product was administered to both legs at a dose of 6 U/kg body weight (3 U/kg for each leg); in the case of unilateral involvement (<italic>n</italic> = 48, hemiplegia), it was administered to the spastic leg at a dose of 4 U/kg body weight.</p><p>For the secondary analyses of this phase III clinical trial, intention-to-treat (ITT) analyses were performed. Continuous variables were presented as means and standard deviations, and categorical variables were presented as frequencies and percentages. Chi-square tests were performed to analyze the efficacy of BoNT injection in terms of injection history, paralysis type, and GMFCS level at 6, 12, and 24 weeks after the injection. Analysis of linear-by-linear associations of the proportion of children in whom the treatment was effective (PRS &#x02265; 2), which was performed with SPSS software, version 17.0 (SPSS for Windows 12.0, Chicago, IL, USA), and SAS software version 9.4 (SAS Institute, Cary, NC, USA) allowed examination according to GMFCS level. Multivariate logistic regression analyses were performed to identify the factors that affect the outcome of BoNT on observational gait pattern (PRS) and motor function (GMFM-88). The following variables were treated as candidates for the purpose of determining associations with the level of responsiveness to BoNT: (1) age; (2) history of previous BoNT injections (yes vs. none; more than one vs. one or none; more than two vs. two or fewer); (3) baseline total PRS score; (4) baseline GMFM-88 total score; (5) GMFCS level; and (6) paralysis type of CP (i.e., unilateral or bilateral involvement).</p></sec></body><back><ack><title>Acknowledgments</title><p>Phase III clinical trial was funded by Hugel. </p></ack><app-group><app id="app1-toxins-09-00253"><title>Supplementary Materials</title><p>The following are available online at <uri xlink:href="www.mdpi.com/2072-6651/9/8/253/s1">www.mdpi.com/2072-6651/9/8/253/s1</uri>, Table S1: Multivariate regression analyses of variables on outcome (PRS &#x02265; 2) at 12 weeks for botulinum toxin injection, previous injection groups: yes vs. none, Table S2: Multivariate regression analyses of variables on outcome (PRS &#x02265; 2) at 24 weeks for botulinum toxin injection, previous injection groups: yes vs. none.</p><supplementary-material content-type="local-data" id="toxins-09-00253-s001"><media xlink:href="toxins-09-00253-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Jeong-Yi Kwon, Hyun Jung Chang and Bo Young Hong conceived and designed the experiments; Bo Young Hong, Sang-Jee Lee, Soyoung Lee, Hyun Jung Chang, Joo Hyun Park, Jeong-Yi Kwon performed the experiments; Bo Young Hong analyzed the data; Jeong-Yi Kwon performed important decision making in experiments; Bo Young Hong wrote the paper and it was proofread by Jeong-Yi Kwon, Hyun Jung Chang.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest with respect to the research, authorship, and/or publication of this article.</p></notes><ref-list><title>References</title><ref id="B1-toxins-09-00253"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bax</surname><given-names>M.</given-names></name><name><surname>Goldstein</surname><given-names>M.</given-names></name><name><surname>Rosenbaum</surname><given-names>P.</given-names></name><name><surname>Leviton</surname><given-names>A.</given-names></name><name><surname>Paneth</surname><given-names>N.</given-names></name><name><surname>Dan</surname><given-names>B.</given-names></name><name><surname>Jacobsson</surname><given-names>B.</given-names></name><name><surname>Damiano</surname><given-names>D.</given-names></name></person-group><article-title>Executive Committee for the Definition of Cerebral Palsy. Proposed definition and classification of cerebral palsy, April 2005</article-title><source>Dev. Med. Child Neurol.</source><year>2005</year><volume>47</volume><fpage>571</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1017/S001216220500112X</pub-id><pub-id pub-id-type="pmid">16108461</pub-id></element-citation></ref><ref id="B2-toxins-09-00253"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuban</surname><given-names>K.C.</given-names></name><name><surname>Leviton</surname><given-names>A.</given-names></name></person-group><article-title>Cerebral palsy</article-title><source>N. Engl. J. Med.</source><year>1994</year><volume>330</volume><fpage>188</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1056/NEJM199401203300308</pub-id><pub-id pub-id-type="pmid">8264743</pub-id></element-citation></ref><ref id="B3-toxins-09-00253"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koman</surname><given-names>L.A.</given-names></name><name><surname>Smith</surname><given-names>B.P.</given-names></name><name><surname>Shilt</surname><given-names>J.S.</given-names></name></person-group><article-title>Cerebral palsy</article-title><source>Lancet</source><year>2004</year><volume>363</volume><fpage>1619</fpage><lpage>1631</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(04)16207-7</pub-id><pub-id pub-id-type="pmid">15145637</pub-id></element-citation></ref><ref id="B4-toxins-09-00253"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mutch</surname><given-names>L.</given-names></name><name><surname>Alberman</surname><given-names>E.</given-names></name><name><surname>Hagberg</surname><given-names>B.</given-names></name><name><surname>Kodama</surname><given-names>K.</given-names></name><name><surname>Perat</surname><given-names>M.V.</given-names></name></person-group><article-title>Cerebral palsy epidemiology: Where are we now and where are we going?</article-title><source>Dev. Med. Child Neurol.</source><year>1992</year><volume>34</volume><fpage>547</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1111/j.1469-8749.1992.tb11479.x</pub-id><pub-id pub-id-type="pmid">1612216</pub-id></element-citation></ref><ref id="B5-toxins-09-00253"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeargin-Allsopp</surname><given-names>M.</given-names></name><name><surname>Van Naarden Braun</surname><given-names>K.</given-names></name><name><surname>Doernberg</surname><given-names>N.S.</given-names></name><name><surname>Benedict</surname><given-names>R.E.</given-names></name><name><surname>Kirby</surname><given-names>R.S.</given-names></name><name><surname>Durkin</surname><given-names>M.S.</given-names></name></person-group><article-title>Prevalence of cerebral palsy in 8-year-old children in three areas of the united states in 2002: A multisite collaboration</article-title><source>Pediatrics</source><year>2008</year><volume>121</volume><fpage>547</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1542/peds.2007-1270</pub-id><pub-id pub-id-type="pmid">18310204</pub-id></element-citation></ref><ref id="B6-toxins-09-00253"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wichers</surname><given-names>M.J.</given-names></name><name><surname>Odding</surname><given-names>E.</given-names></name><name><surname>Stam</surname><given-names>H.J.</given-names></name><name><surname>van Nieuwenhuizen</surname><given-names>O.</given-names></name></person-group><article-title>Clinical presentation, associated disorders and aetiological moments in cerebral palsy: A dutch population-based study</article-title><source>Disabil. Rehabil.</source><year>2005</year><volume>27</volume><fpage>583</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1080/09638280400018445</pub-id><pub-id pub-id-type="pmid">16019867</pub-id></element-citation></ref><ref id="B7-toxins-09-00253"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palisano</surname><given-names>R.J.</given-names></name><name><surname>Hanna</surname><given-names>S.E.</given-names></name><name><surname>Rosenbaum</surname><given-names>P.L.</given-names></name><name><surname>Russell</surname><given-names>D.J.</given-names></name><name><surname>Walter</surname><given-names>S.D.</given-names></name><name><surname>Wood</surname><given-names>E.P.</given-names></name><name><surname>Raina</surname><given-names>P.S.</given-names></name><name><surname>Galuppi</surname><given-names>B.E.</given-names></name></person-group><article-title>Validation of a model of gross motor function for children with cerebral palsy</article-title><source>Phys. Ther.</source><year>2000</year><volume>80</volume><fpage>974</fpage><lpage>985</lpage><pub-id pub-id-type="pmid">11002433</pub-id></element-citation></ref><ref id="B8-toxins-09-00253"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagglund</surname><given-names>G.</given-names></name><name><surname>Andersson</surname><given-names>S.</given-names></name><name><surname>Duppe</surname><given-names>H.</given-names></name><name><surname>Lauge-Pedersen</surname><given-names>H.</given-names></name><name><surname>Nordmark</surname><given-names>E.</given-names></name><name><surname>Westbom</surname><given-names>L.</given-names></name></person-group><article-title>Prevention of dislocation of the hip in children with cerebral palsy. The first ten years of a population-based prevention programme</article-title><source>J. Bone Jt. Surg. Br.</source><year>2005</year><volume>87</volume><fpage>95</fpage><lpage>101</lpage></element-citation></ref><ref id="B9-toxins-09-00253"><label>9.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Feldman</surname><given-names>R.G.</given-names></name><name><surname>Yang</surname><given-names>R.R.</given-names></name><name><surname>Koella</surname><given-names>W.P.</given-names></name></person-group><source>Spasticity: Disordered Motor Control</source><publisher-name>Year Book Medical Publishers</publisher-name><publisher-loc>Chicago, IL, USA</publisher-loc><year>1980</year><fpage>485</fpage><lpage>495</lpage></element-citation></ref><ref id="B10-toxins-09-00253"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagglund</surname><given-names>G.</given-names></name><name><surname>Wagner</surname><given-names>P.</given-names></name></person-group><article-title>Development of spasticity with age in a total population of children with cerebral palsy</article-title><source>BMC Musculoskelet. Disord.</source><year>2008</year><volume>9</volume><elocation-id>150</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2474-9-150</pub-id><pub-id pub-id-type="pmid">18990204</pub-id></element-citation></ref><ref id="B11-toxins-09-00253"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>E.M.</given-names></name></person-group><article-title>Spasticity management: An overview</article-title><source>J. Child Neurol.</source><year>2001</year><volume>16</volume><fpage>16</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1177/088307380101600104</pub-id><pub-id pub-id-type="pmid">11225951</pub-id></element-citation></ref><ref id="B12-toxins-09-00253"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strobl</surname><given-names>W.</given-names></name><name><surname>Theologis</surname><given-names>T.</given-names></name><name><surname>Brunner</surname><given-names>R.</given-names></name><name><surname>Kocer</surname><given-names>S.</given-names></name><name><surname>Viehweger</surname><given-names>E.</given-names></name><name><surname>Pascual-Pascual</surname><given-names>I.</given-names></name><name><surname>Placzek</surname><given-names>R.</given-names></name></person-group><article-title>Best clinical practice in botulinum toxin treatment for children with cerebral palsy</article-title><source>Toxins (Basel)</source><year>2015</year><volume>7</volume><fpage>1629</fpage><lpage>1648</lpage><pub-id pub-id-type="doi">10.3390/toxins7051629</pub-id><pub-id pub-id-type="pmid">25969944</pub-id></element-citation></ref><ref id="B13-toxins-09-00253"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahraman</surname><given-names>A.</given-names></name><name><surname>Seyhan</surname><given-names>K.</given-names></name><name><surname>Deger</surname><given-names>U.</given-names></name><name><surname>Kutluturk</surname><given-names>S.</given-names></name><name><surname>Mutlu</surname><given-names>A.</given-names></name></person-group><article-title>Should botulinum toxin a injections be repeated in children with cerebral palsy? A systematic review</article-title><source>Dev. Med. Child Neurol.</source><year>2016</year><volume>58</volume><fpage>910</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1111/dmcn.13135</pub-id><pub-id pub-id-type="pmid">27103334</pub-id></element-citation></ref><ref id="B14-toxins-09-00253"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pirazzini</surname><given-names>M.</given-names></name><name><surname>Rossetto</surname><given-names>O.</given-names></name><name><surname>Eleopra</surname><given-names>R.</given-names></name><name><surname>Montecucco</surname><given-names>C.</given-names></name></person-group><article-title>Botulinum neurotoxins: Biology, pharmacology, and toxicology</article-title><source>Pharmacol. Rev.</source><year>2017</year><volume>69</volume><fpage>200</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1124/pr.116.012658</pub-id><pub-id pub-id-type="pmid">28356439</pub-id></element-citation></ref><ref id="B15-toxins-09-00253"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koman</surname><given-names>L.A.</given-names></name><name><surname>Mooney</surname><given-names>J.F.</given-names><suffix>3rd</suffix></name><name><surname>Smith</surname><given-names>B.</given-names></name><name><surname>Goodman</surname><given-names>A.</given-names></name><name><surname>Mulvaney</surname><given-names>T.</given-names></name></person-group><article-title>Management of cerebral palsy with botulinum-a toxin: Preliminary investigation</article-title><source>J. Pediatr. Orthop.</source><year>1993</year><volume>13</volume><fpage>489</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1097/01241398-199307000-00013</pub-id><pub-id pub-id-type="pmid">8370782</pub-id></element-citation></ref><ref id="B16-toxins-09-00253"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pirazzini</surname><given-names>M.</given-names></name><name><surname>Azarnia Tehran</surname><given-names>D.</given-names></name><name><surname>Leka</surname><given-names>O.</given-names></name><name><surname>Zanetti</surname><given-names>G.</given-names></name><name><surname>Rossetto</surname><given-names>O.</given-names></name><name><surname>Montecucco</surname><given-names>C.</given-names></name></person-group><article-title>On the translocation of botulinum and tetanus neurotoxins across the membrane of acidic intracellular compartments</article-title><source>Biochim. Biophys. Acta</source><year>2016</year><volume>1858</volume><fpage>467</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2015.08.014</pub-id><pub-id pub-id-type="pmid">26307528</pub-id></element-citation></ref><ref id="B17-toxins-09-00253"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naidu</surname><given-names>K.</given-names></name><name><surname>Smith</surname><given-names>K.</given-names></name><name><surname>Sheedy</surname><given-names>M.</given-names></name><name><surname>Adair</surname><given-names>B.</given-names></name><name><surname>Yu</surname><given-names>X.</given-names></name><name><surname>Graham</surname><given-names>H.K.</given-names></name></person-group><article-title>Systemic adverse events following botulinum toxin a therapy in children with cerebral palsy</article-title><source>Dev. Med. Child Neurol.</source><year>2010</year><volume>52</volume><fpage>139</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1111/j.1469-8749.2009.03583.x</pub-id><pub-id pub-id-type="pmid">20412252</pub-id></element-citation></ref><ref id="B18-toxins-09-00253"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molenaers</surname><given-names>G.</given-names></name><name><surname>Schorkhuber</surname><given-names>V.</given-names></name><name><surname>Fagard</surname><given-names>K.</given-names></name><name><surname>Van Campenhout</surname><given-names>A.</given-names></name><name><surname>De Cat</surname><given-names>J.</given-names></name><name><surname>Pauwels</surname><given-names>P.</given-names></name><name><surname>Ortibus</surname><given-names>E.</given-names></name><name><surname>De Cock</surname><given-names>P.</given-names></name><name><surname>Desloovere</surname><given-names>K.</given-names></name></person-group><article-title>Long-term use of botulinum toxin type a in children with cerebral palsy: Treatment consistency</article-title><source>Eur. J. Paediatr. Neurol.</source><year>2009</year><volume>13</volume><fpage>421</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1016/j.ejpn.2008.07.008</pub-id><pub-id pub-id-type="pmid">18977158</pub-id></element-citation></ref><ref id="B19-toxins-09-00253"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moeini-Naghani</surname><given-names>I.</given-names></name><name><surname>Hashemi-Zonouz</surname><given-names>T.</given-names></name><name><surname>Jabbari</surname><given-names>B.</given-names></name></person-group><article-title>Botulinum toxin treatment of spasticity in adults and children</article-title><source>Semin. Neurol.</source><year>2016</year><volume>36</volume><fpage>64</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1055/s-0036-1571847</pub-id><pub-id pub-id-type="pmid">26866498</pub-id></element-citation></ref><ref id="B20-toxins-09-00253"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scholtes</surname><given-names>V.A.</given-names></name><name><surname>Dallmeijer</surname><given-names>A.J.</given-names></name><name><surname>Knol</surname><given-names>D.L.</given-names></name><name><surname>Speth</surname><given-names>L.A.</given-names></name><name><surname>Maathuis</surname><given-names>C.G.</given-names></name><name><surname>Jongerius</surname><given-names>P.H.</given-names></name><name><surname>Becher</surname><given-names>J.G.</given-names></name></person-group><article-title>Effect of multilevel botulinum toxin a and comprehensive rehabilitation on gait in cerebral palsy</article-title><source>Pediatr. Neurol.</source><year>2007</year><volume>36</volume><fpage>30</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2006.09.010</pub-id><pub-id pub-id-type="pmid">17162194</pub-id></element-citation></ref><ref id="B21-toxins-09-00253"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lidman</surname><given-names>G.</given-names></name><name><surname>Nachemson</surname><given-names>A.</given-names></name><name><surname>Peny-Dahlstrand</surname><given-names>M.</given-names></name><name><surname>Himmelmann</surname><given-names>K.</given-names></name></person-group><article-title>Botulinum toxin a injections and occupational therapy in children with unilateral spastic cerebral palsy: A randomized controlled trial</article-title><source>Dev. Med. Child Neurol.</source><year>2015</year><volume>57</volume><fpage>754</fpage><lpage>761</lpage><pub-id pub-id-type="doi">10.1111/dmcn.12739</pub-id><pub-id pub-id-type="pmid">25808577</pub-id></element-citation></ref><ref id="B22-toxins-09-00253"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinen</surname><given-names>F.</given-names></name><name><surname>Molenaers</surname><given-names>G.</given-names></name><name><surname>Fairhurst</surname><given-names>C.</given-names></name><name><surname>Carr</surname><given-names>L.J.</given-names></name><name><surname>Desloovere</surname><given-names>K.</given-names></name><name><surname>Chaleat Valayer</surname><given-names>E.</given-names></name><name><surname>Morel</surname><given-names>E.</given-names></name><name><surname>Papavassiliou</surname><given-names>A.S.</given-names></name><name><surname>Tedroff</surname><given-names>K.</given-names></name><name><surname>Ignacio Pascual-Pascual</surname><given-names>S.</given-names></name><etal/></person-group><article-title>European consensus Table 2006 on botulinum toxin for children with cerebral palsy</article-title><source>Eur. J. Paediatr. Neurol.</source><year>2006</year><volume>10</volume><fpage>215</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1016/j.ejpn.2006.08.006</pub-id><pub-id pub-id-type="pmid">17097905</pub-id></element-citation></ref><ref id="B23-toxins-09-00253"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Gao</surname><given-names>B.</given-names></name></person-group><article-title>A dose-response relationship research on botulinum toxin type a local intramuscular injections of lower extremity spasticity in children with cerebral palsy</article-title><source>Childs Nerv. Syst.</source><year>2008</year><volume>24</volume><fpage>545</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1007/s00381-007-0571-7</pub-id><pub-id pub-id-type="pmid">18297290</pub-id></element-citation></ref><ref id="B24-toxins-09-00253"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>R.</given-names></name><name><surname>Jasinski</surname><given-names>M.</given-names></name><name><surname>Maciag-Tymecka</surname><given-names>I.</given-names></name><name><surname>Michalowska-Mrozek</surname><given-names>J.</given-names></name><name><surname>Bonikowski</surname><given-names>M.</given-names></name><name><surname>Carr</surname><given-names>L.</given-names></name><name><surname>MacLean</surname><given-names>J.</given-names></name><name><surname>Lin</surname><given-names>J.P.</given-names></name><name><surname>Lynch</surname><given-names>B.</given-names></name><name><surname>Theologis</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Botulinum toxin treatment of spasticity in diplegic cerebral palsy: A randomized, double-blind, placebo-controlled, dose-ranging study</article-title><source>Dev. Med. Child Neurol.</source><year>2002</year><volume>44</volume><fpage>666</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1111/j.1469-8749.2002.tb00268.x</pub-id><pub-id pub-id-type="pmid">12418791</pub-id></element-citation></ref><ref id="B25-toxins-09-00253"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryll</surname><given-names>U.</given-names></name><name><surname>Bastiaenen</surname><given-names>C.</given-names></name><name><surname>De Bie</surname><given-names>R.</given-names></name><name><surname>Staal</surname><given-names>B.</given-names></name></person-group><article-title>Effects of leg muscle botulinum toxin a injections on walking in children with spasticity-related cerebral palsy: A systematic review</article-title><source>Dev. Med. Child Neurol.</source><year>2011</year><volume>53</volume><fpage>210</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1111/j.1469-8749.2010.03890.x</pub-id><pub-id pub-id-type="pmid">21291464</pub-id></element-citation></ref><ref id="B26-toxins-09-00253"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>D.H.</given-names></name><name><surname>Sung</surname><given-names>I.Y.</given-names></name></person-group><article-title>The influence of physical therapy and anti-botulinum toxin antibody on the efficacy of botulinum toxin&#x02014;A injections in children with spastic cerebral palsy</article-title><source>Dev. Neurorehabil.</source><year>2014</year><volume>17</volume><fpage>414</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.3109/17518423.2014.938834</pub-id><pub-id pub-id-type="pmid">25372070</pub-id></element-citation></ref><ref id="B27-toxins-09-00253"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrmann</surname><given-names>J.</given-names></name><name><surname>Geth</surname><given-names>K.</given-names></name><name><surname>Mall</surname><given-names>V.</given-names></name><name><surname>Bigalke</surname><given-names>H.</given-names></name><name><surname>Schulte Monting</surname><given-names>J.</given-names></name><name><surname>Linder</surname><given-names>M.</given-names></name><name><surname>Kirschner</surname><given-names>J.</given-names></name><name><surname>Berweck</surname><given-names>S.</given-names></name><name><surname>Korinthenberg</surname><given-names>R.</given-names></name><name><surname>Heinen</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Clinical impact of antibody formation to botulinum toxin a in children</article-title><source>Ann. Neurol.</source><year>2004</year><volume>55</volume><fpage>732</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1002/ana.20098</pub-id><pub-id pub-id-type="pmid">15122715</pub-id></element-citation></ref><ref id="B28-toxins-09-00253"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>K.</given-names></name><name><surname>Shin</surname><given-names>H.I.</given-names></name><name><surname>Kwon</surname><given-names>B.S.</given-names></name><name><surname>Kim</surname><given-names>S.J.</given-names></name><name><surname>Jung</surname><given-names>I.Y.</given-names></name><name><surname>Bang</surname><given-names>M.S.</given-names></name></person-group><article-title>Neuronox versus botox for spastic equinus gait in children with cerebral palsy: A randomized, double-blinded, controlled multicenter clinical trial</article-title><source>Dev. Med. Child Neurol.</source><year>2011</year><volume>53</volume><fpage>239</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1111/j.1469-8749.2010.03830.x</pub-id><pub-id pub-id-type="pmid">21087238</pub-id></element-citation></ref><ref id="B29-toxins-09-00253"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fazzi</surname><given-names>E.</given-names></name><name><surname>Maraucci</surname><given-names>I.</given-names></name><name><surname>Torrielli</surname><given-names>S.</given-names></name><name><surname>Motta</surname><given-names>F.</given-names></name><name><surname>Lanzi</surname><given-names>G.</given-names></name></person-group><article-title>Factors predicting the efficacy of botulinum toxin&#x02014;A treatment of the lower limb in children with cerebral palsy</article-title><source>J. Child Neurol.</source><year>2005</year><volume>20</volume><fpage>661</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1177/08830738050200080501</pub-id><pub-id pub-id-type="pmid">16225811</pub-id></element-citation></ref><ref id="B30-toxins-09-00253"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fattal-Valevski</surname><given-names>A.</given-names></name><name><surname>Domenievitz</surname><given-names>D.</given-names></name><name><surname>Giladi</surname><given-names>N.</given-names></name><name><surname>Wientroub</surname><given-names>S.</given-names></name><name><surname>Hayek</surname><given-names>S.</given-names></name></person-group><article-title>Long-term effect of repeated injections of botulinum toxin in children with cerebral palsy: A prospective study</article-title><source>J. Child Orthop.</source><year>2008</year><volume>2</volume><fpage>29</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1007/s11832-007-0075-8</pub-id><pub-id pub-id-type="pmid">19308600</pub-id></element-citation></ref><ref id="B31-toxins-09-00253"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tedroff</surname><given-names>K.</given-names></name><name><surname>Granath</surname><given-names>F.</given-names></name><name><surname>Forssberg</surname><given-names>H.</given-names></name><name><surname>Haglund-Akerlind</surname><given-names>Y.</given-names></name></person-group><article-title>Long-term effects of botulinum toxin a in children with cerebral palsy</article-title><source>Dev. Med. Child Neurol.</source><year>2009</year><volume>51</volume><fpage>120</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1111/j.1469-8749.2008.03189.x</pub-id><pub-id pub-id-type="pmid">19191845</pub-id></element-citation></ref><ref id="B32-toxins-09-00253"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>H.J.</given-names></name><name><surname>Hong</surname><given-names>B.Y.</given-names></name><name><surname>Lee</surname><given-names>S.J.</given-names></name><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Park</surname><given-names>J.H.</given-names></name><name><surname>Kwon</surname><given-names>J.Y.</given-names></name></person-group><article-title>Efficacy and safety of letibotulinum toxin a for the treatment of dynamic equinus foot deformity in children with cerebral palsy: A randomized controlled trial</article-title><source>Toxins (Basel)</source><year>2017</year><volume>9</volume><elocation-id>252</elocation-id></element-citation></ref><ref id="B33-toxins-09-00253"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koman</surname><given-names>L.A.</given-names></name><name><surname>Mooney</surname><given-names>J.F.</given-names><suffix>3rd</suffix></name><name><surname>Smith</surname><given-names>B.P.</given-names></name><name><surname>Goodman</surname><given-names>A.</given-names></name><name><surname>Mulvaney</surname><given-names>T.</given-names></name></person-group><article-title>Management of spasticity in cerebral palsy with botulinum-a toxin: Report of a preliminary, randomized, double-blind trial</article-title><source>J. Pediatr. Orthop.</source><year>1994</year><volume>14</volume><fpage>299</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1097/01241398-199405000-00005</pub-id><pub-id pub-id-type="pmid">8006158</pub-id></element-citation></ref><ref id="B34-toxins-09-00253"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>A.</given-names></name><name><surname>Diamond</surname><given-names>M.</given-names></name><name><surname>Johnston</surname><given-names>M.V.</given-names></name><name><surname>Daffner</surname><given-names>C.</given-names></name></person-group><article-title>Effects of botulinum toxin a on upper limb spasticity in children with cerebral palsy</article-title><source>Am. J. Phys. Med. Rehabil.</source><year>2000</year><volume>79</volume><fpage>53</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1097/00002060-200001000-00012</pub-id><pub-id pub-id-type="pmid">10678604</pub-id></element-citation></ref><ref id="B35-toxins-09-00253"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papavasiliou</surname><given-names>A.S.</given-names></name><name><surname>Rapidi</surname><given-names>C.A.</given-names></name><name><surname>Filiopoulos</surname><given-names>C.</given-names></name><name><surname>Rizou</surname><given-names>C.</given-names></name><name><surname>Skouteli</surname><given-names>H.N.</given-names></name></person-group><article-title>Evaluation of a multimodal management of prematurity-related spasticity</article-title><source>Pediatr. Neurol.</source><year>2006</year><volume>35</volume><fpage>400</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2006.08.003</pub-id><pub-id pub-id-type="pmid">17138009</pub-id></element-citation></ref><ref id="B36-toxins-09-00253"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yap</surname><given-names>R.</given-names></name><name><surname>Majnemer</surname><given-names>A.</given-names></name><name><surname>Benaroch</surname><given-names>T.</given-names></name><name><surname>Cantin</surname><given-names>M.A.</given-names></name></person-group><article-title>Determinants of responsiveness to botulinum toxin, casting, and bracing in the treatment of spastic equinus in children with cerebral palsy</article-title><source>Dev. Med. Child Neurol.</source><year>2010</year><volume>52</volume><fpage>186</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1111/j.1469-8749.2009.03365.x</pub-id><pub-id pub-id-type="pmid">20412253</pub-id></element-citation></ref><ref id="B37-toxins-09-00253"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pascual-Pascual</surname><given-names>S.I.</given-names></name><name><surname>Pascual-Castroviejo</surname><given-names>I.</given-names></name><name><surname>Ruiz</surname><given-names>P.J.</given-names></name></person-group><article-title>Treating spastic equinus foot from cerebral palsy with botulinum toxin type a: What factors influence the results?: An analysis of 189 consecutive cases</article-title><source>Am. J. Phys. Med. Rehabil.</source><year>2011</year><volume>90</volume><fpage>554</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1097/PHM.0b013e31821f6c40</pub-id><pub-id pub-id-type="pmid">21765274</pub-id></element-citation></ref><ref id="B38-toxins-09-00253"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linder</surname><given-names>M.</given-names></name><name><surname>Schindler</surname><given-names>G.</given-names></name><name><surname>Michaelis</surname><given-names>U.</given-names></name><name><surname>Stein</surname><given-names>S.</given-names></name><name><surname>Kirschner</surname><given-names>J.</given-names></name><name><surname>Mall</surname><given-names>V.</given-names></name><name><surname>Berweck</surname><given-names>S.</given-names></name><name><surname>Korinthenberg</surname><given-names>R.</given-names></name><name><surname>Heinen</surname><given-names>F.</given-names></name></person-group><article-title>Medium-term functional benefits in children with cerebral palsy treated with botulinum toxin type a: 1-year follow-up using gross motor function measure</article-title><source>Eur. J. Neurol.</source><year>2001</year><volume>8</volume><fpage>120</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1046/j.1468-1331.2001.00044.x</pub-id><pub-id pub-id-type="pmid">11851740</pub-id></element-citation></ref><ref id="B39-toxins-09-00253"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenbaum</surname><given-names>P.L.</given-names></name><name><surname>Walter</surname><given-names>S.D.</given-names></name><name><surname>Hanna</surname><given-names>S.E.</given-names></name><name><surname>Palisano</surname><given-names>R.J.</given-names></name><name><surname>Russell</surname><given-names>D.J.</given-names></name><name><surname>Raina</surname><given-names>P.</given-names></name><name><surname>Wood</surname><given-names>E.</given-names></name><name><surname>Bartlett</surname><given-names>D.J.</given-names></name><name><surname>Galuppi</surname><given-names>B.E.</given-names></name></person-group><article-title>Prognosis for gross motor function in cerebral palsy: Creation of motor development curves</article-title><source>JAMA</source><year>2002</year><volume>288</volume><fpage>1357</fpage><lpage>1363</lpage><pub-id pub-id-type="doi">10.1001/jama.288.11.1357</pub-id><pub-id pub-id-type="pmid">12234229</pub-id></element-citation></ref><ref id="B40-toxins-09-00253"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Damiano</surname><given-names>D.L.</given-names></name><name><surname>Abel</surname><given-names>M.F.</given-names></name></person-group><article-title>Relation of gait analysis to gross motor function in cerebral palsy</article-title><source>Dev. Med. Child Neurol.</source><year>1996</year><volume>38</volume><fpage>389</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1111/j.1469-8749.1996.tb15097.x</pub-id><pub-id pub-id-type="pmid">8698147</pub-id></element-citation></ref><ref id="B41-toxins-09-00253"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>A.P.</given-names></name><name><surname>Ade-Hall</surname><given-names>R.A.</given-names></name><name><surname>Smith</surname><given-names>C.T.</given-names></name><name><surname>Rosenbloom</surname><given-names>L.</given-names></name><name><surname>Walsh</surname><given-names>H.P.</given-names></name><name><surname>Mohamed</surname><given-names>K.</given-names></name><name><surname>Williamson</surname><given-names>P.R.</given-names></name></person-group><article-title>Two-year placebo-controlled trial of botulinum toxin a for leg spasticity in cerebral palsy</article-title><source>Neurology</source><year>2008</year><volume>71</volume><fpage>122</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000316801.74683.c0</pub-id><pub-id pub-id-type="pmid">18606966</pub-id></element-citation></ref><ref id="B42-toxins-09-00253"><label>42.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Dianne</surname><given-names>J.R.</given-names></name><name><surname>Peter</surname><given-names>L.R.</given-names></name><name><surname>Lisa</surname><given-names>M.A.</given-names></name><name><surname>Mary</surname><given-names>L.</given-names></name></person-group><source>Gross Motor Function Measure (Gmfm-66 &#x00026; Gmfm-88) User&#x02018;s Manual</source><publisher-name>Mac Keith Press</publisher-name><publisher-loc>London, UK</publisher-loc><year>2002</year></element-citation></ref><ref id="B43-toxins-09-00253"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alotaibi</surname><given-names>M.</given-names></name><name><surname>Long</surname><given-names>T.</given-names></name><name><surname>Kennedy</surname><given-names>E.</given-names></name><name><surname>Bavishi</surname><given-names>S.</given-names></name></person-group><article-title>The efficacy of gmfm-88 and gmfm-66 to detect changes in gross motor function in children with cerebral palsy (cp): A literature review</article-title><source>Disabil. Rehabil.</source><year>2014</year><volume>36</volume><fpage>617</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.3109/09638288.2013.805820</pub-id><pub-id pub-id-type="pmid">23802141</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="toxins-09-00253-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">toxins-09-00253-t001_Table 1</object-id><label>Table 1</label><caption><p>Differences in physician&#x02019;s rating scale (PRS) scores at 6 weeks, 12 weeks, and 24 weeks after botulinum toxin injection.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Subgroups</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Baseline&#x02014;6 Weeks </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Baseline&#x02014;12 Weeks </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Baseline&#x02014;24 Weeks </th></tr><tr><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRS &#x0003c; 2</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRS &#x02265; 2</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>p</italic></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRS &#x0003c; 2</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRS &#x02265; 2</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>p</italic></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRS &#x0003c; 2</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRS &#x02265; 2</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>p</italic></th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N (%)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N (%)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N (%)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N (%)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N (%)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N (%)</th></tr></thead><tbody><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Pre-injection History</td><td align="center" valign="middle" rowspan="1" colspan="1">None</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (16.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">40 (83.3)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">11 (22.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">37 (77.1)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">20 (41.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">28 (58.3)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29 (30.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">66 (69.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.074</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 (26.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70 (71.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.658</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47 (50)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47 (50)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.347</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">0&#x02212;1</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (19.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">57 (80.3)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">16 (22.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">55 (77.5)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">28 (39.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">43 (60.6)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23 (31.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49 (68.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.095</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20 (27.8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52 (72.2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.470</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39 (54.2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32 (44.4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.110</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x02264;2</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (20.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">75 (79.8)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">24 (25.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">70 (74.5)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">41 (43.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">52 (55.3)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18 (36.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31 (63.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.032</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 (24.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37 (75.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.892</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26 (53.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23 (46.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.457</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Type</td><td align="center" valign="middle" rowspan="1" colspan="1">Unilateral</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (29.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">34 (70.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">11 (22.9%)</td><td align="center" valign="middle" rowspan="1" colspan="1">37 (77.1%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">22 (46.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">25 (53.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bilateral</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23 (24.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72 (75.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.523</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 (26.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70 (73.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.658</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45 (47.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50 (52.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.95</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">GMFCS level</td><td align="center" valign="middle" rowspan="1" colspan="1">I</td><td align="center" valign="middle" rowspan="1" colspan="1">22 (24.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">68 (75.6%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">20 (22.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">70 (77.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">35 (39.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">54 (60.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">II</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (26.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">25 (73.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">10 (29.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">24 (70.6%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">20 (58.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (41.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (31.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (68.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.809</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (31.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (68.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.562</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 (63.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (36.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.05</td></tr></tbody></table><table-wrap-foot><fn><p>GMFCS: Gross Motor Function Classification System.</p></fn></table-wrap-foot></table-wrap><table-wrap id="toxins-09-00253-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">toxins-09-00253-t002_Table 2</object-id><label>Table 2</label><caption><p>Differences in GMFM-88 scores between baseline and at 12 and 24 weeks after botulinum toxin injection according to number of previous injections.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Interval (Weeks)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Previous Injection</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">GMFM-Total Score</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">GMFM-D Score</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">GMFM-E Score</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SD</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SD</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SD</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic></th></tr></thead><tbody><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">None</td><td align="center" valign="middle" rowspan="1" colspan="1">48</td><td align="center" valign="middle" rowspan="1" colspan="1">2.51</td><td align="center" valign="middle" rowspan="1" colspan="1">3.455</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">2.21</td><td align="center" valign="middle" rowspan="1" colspan="1">4.021</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">3.08</td><td align="center" valign="middle" rowspan="1" colspan="1">3.769</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">95</td><td align="center" valign="middle" rowspan="1" colspan="1">1.69</td><td align="center" valign="middle" rowspan="1" colspan="1">3.246</td><td align="center" valign="middle" rowspan="1" colspan="1">0.164</td><td align="center" valign="middle" rowspan="1" colspan="1">0.86</td><td align="center" valign="middle" rowspan="1" colspan="1">2.838</td><td align="center" valign="middle" rowspan="1" colspan="1">0.042</td><td align="center" valign="middle" rowspan="1" colspan="1">2.75</td><td align="center" valign="middle" rowspan="1" colspan="1">4.654</td><td align="center" valign="middle" rowspan="1" colspan="1">0.665</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">0&#x02013;1</td><td align="center" valign="middle" rowspan="1" colspan="1">71</td><td align="center" valign="middle" rowspan="1" colspan="1">2.11</td><td align="center" valign="middle" rowspan="1" colspan="1">3.035</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.73</td><td align="center" valign="middle" rowspan="1" colspan="1">3.533</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">2.39</td><td align="center" valign="middle" rowspan="1" colspan="1">3.404</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;1</td><td align="center" valign="middle" rowspan="1" colspan="1">72</td><td align="center" valign="middle" rowspan="1" colspan="1">1.82</td><td align="center" valign="middle" rowspan="1" colspan="1">3.610</td><td align="center" valign="middle" rowspan="1" colspan="1">0.612</td><td align="center" valign="middle" rowspan="1" colspan="1">0.90</td><td align="center" valign="middle" rowspan="1" colspan="1">3.086</td><td align="center" valign="middle" rowspan="1" colspan="1">0.137</td><td align="center" valign="middle" rowspan="1" colspan="1">3.32</td><td align="center" valign="middle" rowspan="1" colspan="1">5.126</td><td align="center" valign="middle" rowspan="1" colspan="1">0.206</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x02264;2</td><td align="center" valign="middle" rowspan="1" colspan="1">94</td><td align="center" valign="middle" rowspan="1" colspan="1">1.99</td><td align="center" valign="middle" rowspan="1" colspan="1">3.135</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.56</td><td align="center" valign="middle" rowspan="1" colspan="1">3.355</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">2.38</td><td align="center" valign="middle" rowspan="1" colspan="1">3.957</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.91</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.704</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.896</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.84</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.262</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.216</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.78</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.976</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.070</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">24</td><td align="center" valign="middle" rowspan="1" colspan="1">None</td><td align="center" valign="middle" rowspan="1" colspan="1">47</td><td align="center" valign="middle" rowspan="1" colspan="1">3.26</td><td align="center" valign="middle" rowspan="1" colspan="1">3.941</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">2.49</td><td align="center" valign="middle" rowspan="1" colspan="1">4.133</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">4.91</td><td align="center" valign="middle" rowspan="1" colspan="1">5.77</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">94</td><td align="center" valign="middle" rowspan="1" colspan="1">2.566</td><td align="center" valign="middle" rowspan="1" colspan="1">4.159</td><td align="center" valign="middle" rowspan="1" colspan="1">0.344</td><td align="center" valign="middle" rowspan="1" colspan="1">1.38</td><td align="center" valign="middle" rowspan="1" colspan="1">3.386</td><td align="center" valign="middle" rowspan="1" colspan="1">0.092</td><td align="center" valign="middle" rowspan="1" colspan="1">3.77</td><td align="center" valign="middle" rowspan="1" colspan="1">5.411</td><td align="center" valign="middle" rowspan="1" colspan="1">0.247</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">0&#x02013;1</td><td align="center" valign="middle" rowspan="1" colspan="1">70</td><td align="center" valign="middle" rowspan="1" colspan="1">3.119</td><td align="center" valign="middle" rowspan="1" colspan="1">4.044</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">2.23</td><td align="center" valign="middle" rowspan="1" colspan="1">3.990</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">4.30</td><td align="center" valign="middle" rowspan="1" colspan="1">5.494</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;1</td><td align="center" valign="middle" rowspan="1" colspan="1">71</td><td align="center" valign="middle" rowspan="1" colspan="1">2.480</td><td align="center" valign="middle" rowspan="1" colspan="1">4.132</td><td align="center" valign="middle" rowspan="1" colspan="1">0.356</td><td align="center" valign="middle" rowspan="1" colspan="1">1.28</td><td align="center" valign="middle" rowspan="1" colspan="1">3.296</td><td align="center" valign="middle" rowspan="1" colspan="1">0.126</td><td align="center" valign="middle" rowspan="1" colspan="1">4.00</td><td align="center" valign="middle" rowspan="1" colspan="1">5.619</td><td align="center" valign="middle" rowspan="1" colspan="1">0.749</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x02264;2</td><td align="center" valign="middle" rowspan="1" colspan="1">92</td><td align="center" valign="middle" rowspan="1" colspan="1">2.825</td><td align="center" valign="middle" rowspan="1" colspan="1">4.038</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.92</td><td align="center" valign="middle" rowspan="1" colspan="1">3.847</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">4.10</td><td align="center" valign="middle" rowspan="1" colspan="1">5.475</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.745</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.218</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.913</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.43</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.342</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.448</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.714</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.881</td></tr></tbody></table><table-wrap-foot><fn><p>GMFM: Gross Motor Function Measure, SD: Standard Deviation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="toxins-09-00253-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">toxins-09-00253-t003_Table 3</object-id><label>Table 3</label><caption><p>Multivariate regression analyses of variables on outcome (PRS &#x02265; 2) at 12 weeks after botulinum toxin injection, according to the number of previous injections (none or one, two or more).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Variables</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Coeff</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SE</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">OR</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">95% CI (OR)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic>
<sup>1</sup></th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.1084</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1038</td><td align="center" valign="middle" rowspan="1" colspan="1">0.897</td><td align="center" valign="middle" rowspan="1" colspan="1">0.732</td><td align="center" valign="middle" rowspan="1" colspan="1">1.100</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2960</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Gender</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Male</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.1033</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3986</td><td align="center" valign="middle" rowspan="1" colspan="1">0.902</td><td align="center" valign="middle" rowspan="1" colspan="1">0.413</td><td align="center" valign="middle" rowspan="1" colspan="1">1.970</td><td align="center" valign="middle" rowspan="1" colspan="1">0.7955</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Female</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.000</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PRS Score</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.1924</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0942</td><td align="center" valign="middle" rowspan="1" colspan="1">0.825</td><td align="center" valign="middle" rowspan="1" colspan="1">0.686</td><td align="center" valign="middle" rowspan="1" colspan="1">0.992</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0410</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GMFCS Level</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;I</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.000</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;II</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.4175</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5709</td><td align="center" valign="middle" rowspan="1" colspan="1">0.659</td><td align="center" valign="middle" rowspan="1" colspan="1">0.215</td><td align="center" valign="middle" rowspan="1" colspan="1">2.016</td><td align="center" valign="middle" rowspan="1" colspan="1">0.4645</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;III</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3337</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9564</td><td align="center" valign="middle" rowspan="1" colspan="1">1.396</td><td align="center" valign="middle" rowspan="1" colspan="1">0.214</td><td align="center" valign="middle" rowspan="1" colspan="1">9.100</td><td align="center" valign="middle" rowspan="1" colspan="1">0.7272</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GMFM Score</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0364</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0246</td><td align="center" valign="middle" rowspan="1" colspan="1">1.037</td><td align="center" valign="middle" rowspan="1" colspan="1">0.988</td><td align="center" valign="middle" rowspan="1" colspan="1">1.088</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1393</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Previous injection</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x0003e;1</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.7322</td><td align="center" valign="middle" rowspan="1" colspan="1">0.4405</td><td align="center" valign="middle" rowspan="1" colspan="1">0.481</td><td align="center" valign="middle" rowspan="1" colspan="1">0.203</td><td align="center" valign="middle" rowspan="1" colspan="1">1.140</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0965</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;0&#x02013;1</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.000</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Type</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Bilateral</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.5490</td><td align="center" valign="middle" rowspan="1" colspan="1">0.4737</td><td align="center" valign="middle" rowspan="1" colspan="1">0.578</td><td align="center" valign="middle" rowspan="1" colspan="1">0.228</td><td align="center" valign="middle" rowspan="1" colspan="1">1.462</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2465</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;Unilateral</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup>
<italic>p</italic> Value calculated by logistic regression analysis, GMFCS: Gross Motor Function Classification System, GMFM: Gross Motor Function Measure, OR: Odds Ratio, CI: Confidence Interval.</p></fn></table-wrap-foot></table-wrap><table-wrap id="toxins-09-00253-t004" orientation="portrait" position="float"><object-id pub-id-type="pii">toxins-09-00253-t004_Table 4</object-id><label>Table 4</label><caption><p>Multivariate regression analyses of effects of variables on outcomes (PRS &#x02265; 2) at 24 weeks after botulinum toxin injection according to number of previous injections: more than one vs. one or none.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Variables</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Coeff</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SE</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">OR</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">95% CI (OR)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic>
<sup>1</sup></th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1423</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1040</td><td align="center" valign="middle" rowspan="1" colspan="1">1.153</td><td align="center" valign="middle" rowspan="1" colspan="1">0.940</td><td align="center" valign="middle" rowspan="1" colspan="1">1.414</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1711</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Gender</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Male</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1184</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3771</td><td align="center" valign="middle" rowspan="1" colspan="1">1.126</td><td align="center" valign="middle" rowspan="1" colspan="1">0.538</td><td align="center" valign="middle" rowspan="1" colspan="1">2.358</td><td align="center" valign="middle" rowspan="1" colspan="1">0.7535</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Female</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.000</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PRS Score</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.1747</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0926</td><td align="center" valign="middle" rowspan="1" colspan="1">0.840</td><td align="center" valign="middle" rowspan="1" colspan="1">0.700</td><td align="center" valign="middle" rowspan="1" colspan="1">1.007</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0592</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GMFCS Level</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;I</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.000</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;II</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.8834</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5684</td><td align="center" valign="middle" rowspan="1" colspan="1">0.413</td><td align="center" valign="middle" rowspan="1" colspan="1">0.136</td><td align="center" valign="middle" rowspan="1" colspan="1">1.259</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1201</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;III</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.7753</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9737</td><td align="center" valign="middle" rowspan="1" colspan="1">0.169</td><td align="center" valign="middle" rowspan="1" colspan="1">0.025</td><td align="center" valign="middle" rowspan="1" colspan="1">1.143</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0683</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GMFM Score</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0005</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0240</td><td align="center" valign="middle" rowspan="1" colspan="1">1.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.954</td><td align="center" valign="middle" rowspan="1" colspan="1">1.049</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9850</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Previous injection</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x0003e;1</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.8871</td><td align="center" valign="middle" rowspan="1" colspan="1">0.4256</td><td align="center" valign="middle" rowspan="1" colspan="1">0.412</td><td align="center" valign="middle" rowspan="1" colspan="1">0.179</td><td align="center" valign="middle" rowspan="1" colspan="1">0.948</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0371</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;0&#x02013;1</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.000</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Type</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Bilateral</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1873</td><td align="center" valign="middle" rowspan="1" colspan="1">0.4298</td><td align="center" valign="middle" rowspan="1" colspan="1">1.206</td><td align="center" valign="middle" rowspan="1" colspan="1">0.519</td><td align="center" valign="middle" rowspan="1" colspan="1">2.800</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6630</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;Unilateral</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup>
<italic>p</italic> Value calculated by logistic regression analysis, PRS: Physician&#x02019;s Rating Scale, GMFCS: Gross Motor Function Classification System., OR: Odds Ratio, CI: Confidence Interval.</p></fn></table-wrap-foot></table-wrap></floats-group></article>